|
1
|
Viebahn-Haensler R and Lee A: The Use of
Ozone in Medicine. 5th edition. ODREI-Publishers; Iffezheim: pp.
1482007
|
|
2
|
Nogales CG, Ferrari PH, Kantorovich EO and
Lage-Marques JL: Ozone therapy in medicine and dentistry. J Contemp
Dent Pract. 9:75–84. 2008.PubMed/NCBI
|
|
3
|
Kuroda K, Azuma K, Mori T, Kawamoto K,
Murahata Y, Tsuka T, Osaki T, Ito N, Imagawa T, Itoh F and Okamoto
Y: The safety and anti-tumor effects of ozonated water in vivo. Int
J Mol Sci. 16:25108–25120. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Clavo B, Pérez JL, López L, Suárez G,
Lloret M, Rodríguez V, Macías D, Santana M, Hernández MA,
Martín-Oliva R and Robaina F: Ozone therapy for tumor oxygenation:
A pilot study. Evid Based Complement Alternat Med. 1:93–98. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Graeber TG, Osmanian C, Jacks T, Housman
DE, Koch CJ, Lowe SW and Giaccia AJ: Hypoxia-mediated selection of
cells with diminished apoptotic potential in solid tumours. Nature.
379:88–91. 1996. View
Article : Google Scholar : PubMed/NCBI
|
|
6
|
Bertout JA, Patel SA and Simon MC: The
impact of O2 availability on human cancer. Nat Rev
Cancer. 8:967–975. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Semenza GL: Targeting HIF-1 for cancer
therapy. Nat Rev Cancer. 3:721–732. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Teicher BA: Hypoxia and drug resistance.
Cancer Metastasis Rev. 13:139–168. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Clavo B, Ruiz A, Lloret M, López L, Suárez
G, Macías D, Rodríguez V, Hernández MA, Martín-Oliva R, Quintero S,
et al: Adjuvant ozonetherapy in advanced head and neck tumors: A
comparative study. Evid Based Complement Alternat Med. 1:321–325.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Borrego A, Zamora ZB, González R, Romay C,
Menéndez S, Hernández F, Montero T and Rojas E: Protection by ozone
preconditioning is mediated by the antioxidant system in
cisplatin-induced nephrotoxicity in rats. Mediators Inflamm.
13:13–19. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Borrego A, Zamora ZB, González R, Romay C,
Menéndez S, Hernández F, Berlanga J and Montero T: Ozone/oxygen
mixture modifies the subcellular redistribution of bax protein in
renal tissue from rats treated with cisplatin. Arch Med Res.
37:717–722. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
González R, Borrego A, Zamora Z, Romay C,
Hernández F, Menéndez S, Montero T and Rojas E: Reversion by ozone
treatment of acute nephrotoxicity induced by cisplatin in rats.
Mediators Inflamm. 13:307–312. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Nitta M, Azuma K, Hata K, Takahashi S,
Ogiwara K, Tsuka T, Imagawa T, Yokoe I, Osaki T, Minami S and
Okamoto Y: Systemic and local injections of lupeol inhibit tumor
growth in a melanoma-bearing mouse model. Biomed Rep. 1:641–645.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mukhina IV, Dudina EV, Yakovleva EI,
Zhemarina NV, Prodanecs NN, Evdokimova OS, Manuhina EB and
Dvornikov AV: The dose-dependent effect of ozonated physiological
solution on arterial vasodilation. IOA 17th World Ozone
Congress-Strasbourg 2005. III:3.9–1. 2005.
|
|
15
|
Dutka M, Adamczak M, Kopieczna-Grzebieniak
E, Grabowska-Bochenek R and Wesolowski W: Vasorelaxant activity of
ozone-in vitro studies. Adv Clin Exp Med. 4:391–398. 1998.
|
|
16
|
Brown JM and Wilson WR: Exploiting tumour
hypoxia in cancer treatment. Nat Rev Cancer. 4:437–447. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lunt SJ, Chaudary N and Hill RP: The tumor
microenvironment and metastatic disease. Clin Exp Metastasis.
26:19–34. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Takaki A, Morikawa K, Tsutsui M, Murayama
Y, Tekes E, Yamagishi H, Ohashi J, Yada T, Yanagihara N and
Shimokawa H: Crucial role of nitric oxide synthases system in
endothelium-dependent hyperpolarization in mice. J Exp Med.
205:2053–2063. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amellem O, Löffler M and Pettersen EO:
Regulation of cell proliferation under extreme and moderate
hypoxia: The role of pyrimidine (deoxy)nucleotides. Br J Cancer.
70:857–866. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Gardner LB, Li Q, Park MS, Flanagan WM,
Semenza GL and Dang CV: Hypoxia inhibits G1/S transition through
regulation of p27 expression. J Biol Chem. 276:7919–7926. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Erler JT, Cawthorne CJ, Williams KJ,
Koritzinsky M, Wouters BG, Wilson C, Miller C, Demonacos C,
Stratford IJ and Dive C: Hypoxia-mediated down-regulation of Bid
and Bax in tumors occurs via hypoxia-inducible factor 1-dependent
and -independent mechanisms and contributes to drug resistance. Mol
Cell Biol. 24:2875–2889. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mayes PA, Dolloff NG, Daniel CJ, Liu JJ,
Hart LS, Kuribayashi K, Allen JE, Jee DI, Dorsey JF, Liu YY, et al:
Overcoming hypoxia-induced apoptotic resistance through
combinatorial inhibition of GSK-3β and CDK1. Cancer Res.
71:5265–5275. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Kartalou M and Essigmann JM: Mechanisms of
resistance to cisplatin. Mutat Res. 478:23–43. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Takahashi K: The effect of
cis-Dichlorodiammineplatinum (II) on tumor growth and progress in
the cell cycle. Japanese Journal of Cancer and Chemotherapy.
9:624–631. 1982.(In Japanese). PubMed/NCBI
|
|
25
|
Drewinko B, Brown BW and Gottlieb JA: The
effect of cis-diamminedichloroplatinum (II) on cultured human
lymphoma cells and its therapeutic implications. Cancer Res.
33:3091–3095. 1973.PubMed/NCBI
|
